BioLineRx Ltd. - American Depositary Shares (BLRX)
6.0600
+2.2700 (59.89%)
NASDAQ · Last Trade: May 30th, 12:27 PM EDT
Detailed Quote
Previous Close | 3.790 |
---|---|
Open | 5.870 |
Bid | 6.050 |
Ask | 6.070 |
Day's Range | 5.250 - 7.770 |
52 Week Range | 2.300 - 35.60 |
Volume | 31,448,594 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 24,207 |
Chart
About BioLineRx Ltd. - American Depositary Shares (BLRX)
Biolinerx Ltd is a biopharmaceutical company that focuses on the development of innovative therapies for cancer and other diseases. The company is engaged in the research and clinical development of a diverse pipeline of drug candidates, aiming to address unmet medical needs through cutting-edge technologies and unique approaches. Biolinerx collaborates with various academic institutions and industry partners to enhance its product offerings and accelerate the development of its therapeutic solutions, striving to improve patient outcomes and quality of life in the medical field. Read More
News & Press Releases

Via Benzinga · May 30, 2025
CEO Philip Serlin said that the company has been actively evaluating new assets in the areas of oncology and rare diseases, where it can leverage its expertise after out-licensing Aphexda.
Via Stocktwits · May 27, 2025
Via Benzinga · May 2, 2025

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · January 30, 2025

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via Chartmill · January 30, 2025

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · January 30, 2025

Via Benzinga · January 17, 2025

Via Benzinga · January 17, 2025

Via Benzinga · January 16, 2025

Via Benzinga · January 6, 2025

Via Benzinga · January 6, 2025

Via Benzinga · January 3, 2025

Via Benzinga · November 21, 2024

Via Benzinga · October 11, 2024